Examples of using Coagulation factor in English and their translations into Dutch
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Dried human coagulation factor ix.
Coagulation factor VIII 1000 IU von Willebrand factor 2400 IU.
Nonafact human coagulation factor IX.
Plasma coagulation factor IX is a normal constituent of human plasma.
Nonafact 100 IU/ ml human coagulation factor IX.
People also translate
IU human coagulation factor IX 100 IU/ ml after reconstitution.
The active substance is human coagulation factor IX.
Recombinant coagulation factor VIII octocog alfa.
The active substance is human coagulation factor IX.
Recombinant Coagulation factor VIII, 250 IU/ vial.
NovoSeven contains activated recombinant coagulation factor VII.
A derivative of coagulation factor concentrates.
The active substance is nonacog alfa recombinant coagulation factor IX.
Kogenate Bayer human coagulation factor VIII octocog alfa.
The active substance is moroctocog alfa recombinant coagulation factor VIII.
Helixate NexGen human coagulation factor VIII octocog alfa.
Pharmacotherapeutic group: antihaemorrhagics, blood coagulation factor IX.
Nonacog alfa(recombinant coagulation factor IX) Intravenous use.
Each vial contains nominally 250 IU nonacog alfa recombinant coagulation factor IX.
Turoctocog alfa human coagulation factor VIII rDNA.
are deficient in coagulation factor IX.
Recombinant coagulation factor VIII(octocog alfa) Intravenous use.
Dried or frozen human coagulation factor viii.
Recombinant coagulation factor IX is a glycoprotein that is secreted by genetically engineered mammalian cells derived from a Chinese hamster ovary(CHO) cell line.
RIXUBIS contains recombinant coagulation factor IX nonacog gamma.
solvent for solution for injection Human coagulation factor IX.
BeneFIX contains recombinant coagulation factor IX, nonacog alfa.
Recombinant coagulation factor IX is a recombinant DNA-based protein therapeutic which has structural
The active substance is recombinant coagulation factor VIII octocog alfa.
Patients treated with recombinant coagulation factor VIII should be carefully monitored for the development of inhibitors by appropriate clinical observations